CA2285477A1 - Formulations et procedes de traitement et de prevention de la myelo-encephalite equine due a des protozoaires - Google Patents
Formulations et procedes de traitement et de prevention de la myelo-encephalite equine due a des protozoaires Download PDFInfo
- Publication number
- CA2285477A1 CA2285477A1 CA002285477A CA2285477A CA2285477A1 CA 2285477 A1 CA2285477 A1 CA 2285477A1 CA 002285477 A CA002285477 A CA 002285477A CA 2285477 A CA2285477 A CA 2285477A CA 2285477 A1 CA2285477 A1 CA 2285477A1
- Authority
- CA
- Canada
- Prior art keywords
- treat
- methods
- prevent
- formulations
- equine protozoal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title abstract 5
- 241000283073 Equus caballus Species 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 201000002491 encephalomyelitis Diseases 0.000 title 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 2
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 abstract 2
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 abstract 2
- XQKYUBTUOHHNDV-UHFFFAOYSA-N 2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]-2-(4-fluorophenyl)acetonitrile Chemical compound C1=CC(F)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl XQKYUBTUOHHNDV-UHFFFAOYSA-N 0.000 abstract 2
- 241000146987 Sarcocystis neurona Species 0.000 abstract 2
- 230000001165 anti-coccidial effect Effects 0.000 abstract 2
- QUUTUGLQZLNABV-UHFFFAOYSA-N clazuril Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=CC=C(N2C(NC(=O)C=N2)=O)C=C1Cl QUUTUGLQZLNABV-UHFFFAOYSA-N 0.000 abstract 2
- 229950003606 clazuril Drugs 0.000 abstract 2
- 229960000248 diclazuril Drugs 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 229950005045 letrazuril Drugs 0.000 abstract 2
- 229960000898 toltrazuril Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4247397P | 1997-03-31 | 1997-03-31 | |
| US60/042,473 | 1997-03-31 | ||
| US08/908,257 US5883095A (en) | 1997-08-07 | 1997-08-07 | Formulations and methods to treat and prevent equine protozoal myeloencephalitis |
| US08/908,257 | 1997-08-07 | ||
| PCT/US1998/006340 WO1998043644A1 (fr) | 1997-03-31 | 1998-03-31 | Formulations et procedes de traitement et de prevention de la myelo-encephalite equine due a des protozoaires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2285477A1 true CA2285477A1 (fr) | 1998-10-08 |
| CA2285477C CA2285477C (fr) | 2006-10-10 |
Family
ID=26719285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002285477A Expired - Lifetime CA2285477C (fr) | 1997-03-31 | 1998-03-31 | Formulations et procedes de traitement et de prevention de la myelo-encephalite equine due a des protozoaires |
Country Status (3)
| Country | Link |
|---|---|
| BR (1) | BR9808114A (fr) |
| CA (1) | CA2285477C (fr) |
| WO (1) | WO1998043644A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747476A (en) * | 1996-07-17 | 1998-05-05 | Mortar & Pestle Veterinary Pharmacy, Inc. | Treatment of equine protozoal myeloencephalitis |
| DE19824483A1 (de) * | 1998-06-02 | 1999-12-09 | Bayer Ag | Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon |
| DE69906335T2 (de) * | 1998-10-06 | 2004-02-12 | Mars U.K. Ltd., Slough | Verhaltensstörungen beim tier |
| GB9822681D0 (en) * | 1998-10-16 | 1998-12-09 | Vitabiotics Ltd | Method of treatment |
| US6150361A (en) * | 1998-12-22 | 2000-11-21 | Bayer Corporation | Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| CA2356181A1 (fr) * | 1998-12-22 | 2000-06-29 | Bayer Corporation | Composes de triazineone utilises pour traiter les maladies dues aux sarcocystis, neospora et toxoplasme |
| US6194408B1 (en) * | 1998-12-22 | 2001-02-27 | Bayer Corporation | Triazineone compounds for treating diseases due to Sarcocystis, Neospora and Toxoplasma |
| DE19958388A1 (de) * | 1999-12-03 | 2001-06-07 | Bayer Ag | Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten |
| US6884797B2 (en) * | 2001-03-30 | 2005-04-26 | Robert F. Hofmann | Targeted oxidative therapeutic formulation |
| PL378713A1 (pl) * | 2003-01-16 | 2006-05-15 | Janssen Pharmaceutica N.V. | Kompozycje przeciwpierwotniakowe, zawierające diklazuryl |
| MX2008009818A (es) * | 2008-07-31 | 2010-02-01 | Avi Mex S A De C V Lab | Combinacion coccidicida para uso veterinario. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8602342D0 (en) * | 1986-01-30 | 1986-03-05 | Janssen Pharmaceutica Nv | 5 6-dihydro-2-(substituted phenyl)-1 2 4-triazine-3 5(2h 4h)-diones |
-
1998
- 1998-03-31 BR BR9808114-4A patent/BR9808114A/pt not_active Application Discontinuation
- 1998-03-31 CA CA002285477A patent/CA2285477C/fr not_active Expired - Lifetime
- 1998-03-31 WO PCT/US1998/006340 patent/WO1998043644A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998043644A1 (fr) | 1998-10-08 |
| CA2285477C (fr) | 2006-10-10 |
| BR9808114A (pt) | 2000-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1227899A (en) | Osmotic medicament releasing system | |
| GB2357969A (en) | Improvements in or relating to the treatment of lesions | |
| CA2184242A1 (fr) | Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament | |
| PL309596A1 (en) | Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes | |
| MY124714A (en) | Enzyme treatment | |
| EP0693281A3 (fr) | Formulations pharmaceutiques contenant de la fluoxétine | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| CA2285477A1 (fr) | Formulations et procedes de traitement et de prevention de la myelo-encephalite equine due a des protozoaires | |
| PL347061A1 (en) | Mucosal originated drug delivery systems and animal applications | |
| DK0562705T3 (da) | Anvendelse af L-deprenyl til fremstilling af et lægemiddel til behandling af Cushings sygdom | |
| ZA97596B (en) | Solid instant-release forms of administration and processes for their production | |
| AU5643299A (en) | Humic acid and its use in the treatment of various conditions | |
| CA2221255A1 (fr) | Utilisation de selegiline dans le traitement de pertes d'audition chez des mammiferes | |
| IL118218A0 (en) | Terpenoidic derivatives and pharmaceutical compositions containing them | |
| PL326629A1 (en) | Application of flupyrtin in prophylaxy and therapy of deseases associated with damaged hematopoietic cellular system | |
| GB2277265B (en) | Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema | |
| NZ307601A (en) | Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions | |
| JP2003515563A5 (fr) | ||
| WO2001034632A3 (fr) | Derives de piperidyle diaryle pyrrole a substitution hydroxy aliphatique en tant qu'agents antiprotozoaires | |
| AU1564500A (en) | Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction | |
| EP1143981A4 (fr) | Traitement et prevention d'infections par le vih et d'autres infections virales | |
| MD1051C2 (ro) | Remediu antiherpetic | |
| UA41326C2 (uk) | Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань | |
| OA09771A (en) | Asphodelus composition for increasing white blood cell count. | |
| WO1998025594A3 (fr) | Nouveau traitement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180403 |